The research report "GCC Pharmaceutical Market Opportunity Insight 2025" provides an in-depth analysis about the current market dynamics that includes drivers, trends and opportunities which are subjected to have an influence on the market of the pharmaceutical products in the GCC region. Various important factors that are supported by the governments of the GCC countries for various agents commercialized in the region are also provided in a segmented way in the research report. The impact of the regulatory scenario that is prevailing upon the major key players of the region is also discussed in the report.
The research conducted on the respective subject highlights the distribution of the market based on the profiles of the companies and their respective efforts in increasing the production and value of the product exponentially. The anticipation of the pharmaceutical market in the GCC region is believed to be the result of the factors that are hindering the people of GCC region such as rapid change in the dynamics of the population, geriatric population and most importantly increasing prevalence of lifestyle associated diseases such as diabetes, obesity, cardiovascular diseases.
"GCC Market Offers Unexplored and Exponential Growth Opportunities For Global Pharmaceutical Companies As Imports Accounts For More Than 80% Regional Pharmaceutical Products Sales."
With the increasing disorders associated with lifestyle of the gulf population, the government policies along with regulatory framework became more poised towards the promoting the growth of the pharmaceutical market in the region. Factors like these are most prominent in developing a huge difference and marking an exponential growth rate in the market size of GCC pharmaceutical market in the coming years. Over the years, the branded drugs market has been dominating the market of GCC pharmaceuticals and most pre-dominantly among all the countries included in GCC, Saudi Arabia compiled of maximum share of the market.
Saudi Arabia, among the other gulf countries is a region with major dominant traits. Economic viability, changing legislative and framework are the main driving forces for the establishment of such high-valued pharmaceutical market in the gulf. Slowly and steadily, new frontiers of the pharmaceutical market are making their way to the gulf and imposing their need for the development of generic drug over the market of branded drugs. The alternative form of the drugs available in the market will end up in the up-regulation of the overall market trends by many folds.
“The Growing Demand Of The Generic And Branded Pharmaceuticals That Is Driven By The Various Government Policies And Cost Effective Facilities, Is Considered As A Significant Opportunity For The Drug Manufacturers In The GCC.”
The sales record achieved from the gulf countries establishes Saudi Arabia as an emerging ground for the pharmaceutical market, with UAE and others as a prominent region for expanding the market. The Imported drug market established in the region constitutes a major portion of the GCC pharmaceutical market. More than 80% of the drug utilized in the gulf countries is imported from the major players established in the Western countries. The percent mentioned indicates a huge demand of the drugs either imported or manufactured in the local region. Both aspects of the pharmaceutical market suggest a high demand of the pharmaceutical drugs in the market and eventually a prevailing commercial success.
Introduction to Gulf Cooperation Council (GCC) Pharmaceutical Market
1.1 Overview
1.2 GCC Pharmaceutical Market Analysis
GCC Pharmaceutical Market by Indication - Prevalence and Statistics
2.1 Cancer
2.1.1 Overview
2.1.2 Prevalence by Cancer Type and Gender
2.1.3 Cancer Prevalence and Statistics by GCC Countries
2.2 Diabetes
2.3 HIV/AIDS
2.4 Cardiovascular Diseases
2.4.1 Coronary Heart Disease
2.4.2 Hypertension
2.4.3 Stroke
2.5 Obesity
2.6 Respiratory Disorders
2.6.1 Asthma
2.6.2 Tuberculosis
2.6.3 Influenza and Pneumonia
2.6.4 Other Respiratory Diseases - COPD and Cystic Fibrosis
2.7 Alzheimer's Disease/Dementia
GCC - Regulatory Aspects of Pharmaceuticals
3.1 Gulf Central Committee for Drug Registrations (GCC-DR)
3.2 Regulatory Review Process
3.3 Centralized Registration
3.4 Decentralized Drug Registration Regulation
3.4.1 Saudi Arabia
3.4.2 Kuwait
3.4.3 UAE
3.4.4 Bahrain
3.4.5 Qatar
3.4.6 Oman
3.5 Gulf Joint Procurement Program
GCC - Pharmaceutical Pricing and Reimbursement Policies
4.1 Pricing Policies
4.1.1 In-Patent Pharmaceuticals
4.1.2 Off-Patent and Generic Pharmaceuticals
4.1.3 Locally and Multinational Manufactured Pharmaceuticals
4.2 Procurement and Reimbursement Policies
4.2.1 In-Patent Pharmaceuticals
4.2.2 Off-Patent, Generics and Biosimilars
GCC Pharmaceutical Market by Product
5.1Generics Pharmaceuticals
5.2 Patented and OTC Pharmaceuticals
5.3 Biosimilars
Saudi Arabia Pharmaceutical Market Analysis
6.1 Overview
6.2 Saudi Arabia Pharmaceutical Market by Products
6.3 Saudi Arabia Pharmaceutical Market by Companies
6.4 Saudi Arabia Pharmaceutical Market by Type
UAE Pharmaceutical Market Analysis
7.1 Overview
7.2 UAE Pharmaceuticals Market by Product
7.3 UAE Pharmaceutical Market by Companies
7.4 UAE Pharmaceutical Market by Type
Kuwait Pharmaceutical Market Analysis
8.1 Overview
8.2 Kuwait Pharmaceutical Market by Therapeutic Indication and Products
8.3 Kuwait Pharmaceutical Market by Companies
8.4 Kuwait Pharmaceutical Market by Type
Bahrain Pharmaceutical Market Analysis
9.1 Overview
9.2 Bahrain Pharmaceutical Market by Products
9.3 Bahrain Pharmaceutical market by Companies
9.4 Bahrain Pharmaceutical Market by Product Type
Qatar Pharmaceutical Market Analysis
10.1 Overview
10.2 Qatar Pharmaceutical Market by Type
Oman Pharmaceutical Market Analysis
11.1 Overview
11.2 Oman Pharmaceutical Market by Product Type
GCC Pharmaceutical Market - International Trade
12.1 Import Market
12.2 Pharmaceutical Export Market
GCC Pharmaceutical Market - Clinical Insight
13.1 Overview
13.2 Clinical Trials by Indication
13.2.1 Cancer
13.2.2 Diabetes
13.2.3 CVS Disorders
13.2.4 Respiratory Disorders
13.3 Clinical Insight by GCC Countries
13.3.1 Saudi Arabia
13.3.2 United Arab Emirates
13.3.3 Kuwait
13.3.4 Bahrain
13.3.5 Qatar
13.3.6 Oman
GCC Pharmaceutical Market Drivers
Challenges for GCC Pharmaceutical Market
GCC Pharmaceutical Market Future Outlook - Trends and Opportunities
Competitive Landscape
17.1 Local Pharmaceutical Companies
17.1.1 Julphur Pharmaceuticals
17.1.2 SPIMACO Addwaeih
17.1.3 Qatar Life Pharma
17.1.4 Al Mojil Drug Company
17.1.5 Kuwait Saudi Pharmaceutical Company
17.1.6 YIACO Medical Company
17.1.7 Qatar Pharma
17.1.8 Saja Pharmaceuticals
17.1.9 Oman Pharmaceuticals
17.1.10 Taiba Pharmaceuticals
17.1.11 Gulf Biotech
17.1.12 Bahrain Pharma
17.1.13 Neopharma
17.1.14 Planet Pharmacies
17.1.15 Aljazeera Pharmaceutical Industries
17.1.16 Dallah Pharma
17.1.17 Tabuk Pharmaceuticals
17.1.18 CAD Middle-East Pharmaceutical Company
17.1.19 ACDIMA
17.1.20 AL-Mufid Pharmaceuticals
17.2 Multinational Companies
17.2.1 Novartis
17.2.2 Amgen
17.2.3 Eli - Lilly
17.2.4 Merck
17.2.5 Pfizer
17.2.6 GlaxoSmithKline plc
17.2.7 Roche
17.2.8 Takeda Pharmaceuticals
17.2.9 Teva Pharmaceuticals
17.2.10 AstraZeneca plc
17.2.11 Genentech
17.2.12 Sanofi
Figure 1-1: Pharmaceutical Market Size - Global vs. GCC (US$ Billion), 2018
Figure 1-2: GCC vs. Rest of World - Pharmaceutical Market Size (%), 2018
Figure 1-3: GCC - Population Statistics (Million), 2019
Figure 1-4: GCC - Population by Countries (%), 2019
Figure 1-5: GCC - Healthcare Expenditure by Countries (US$ Billion), 2018
Figure 1-6: GCC - Healthcare Expenditure by Countries (%), 2018
Figure 2-65: Qatar - Cumulative Number of HIV Cases and Patients on Antiretroviral Therapy, 1984 - 2014
Figure 2-66: Qatar - HIV Patients on Anti-Retroviral Therapy, 1984 - 2014
Figure 2-67: Oman - Cumulative HIV Cases, 2014, 2016 and 2018
Figure 2-68: Oman - Cumulative HIV Cases by Gender, 2018
Figure 2-69: Oman - Cumulative HIV Cases by Gender (%), 2018
Figure 2-70: Oman - Cumulative HIV Cases by Age, 2018
Figure 2-71: GCC - Age Standardized Coronary Heart Disease Death Rate by Countries, 2017
Figure 2-72: GCC - CHD Related Deaths by Countries, 2017
Figure 2-73: GCC - CHD Related Deaths by Countries (%), 2017
Figure 2-74: GCC - Age Standardized Hypertension Death Rate by Countries, 2017
Figure 2-75: GCC - Hypertension Related Deaths by Countries, 2017
Figure 2-76: GCC - Hypertension Related Deaths by Countries (%), 2017
Figure 2-77: GCC - Age Standardized Stroke Death Rate by Countries, 2017
Figure 2-78: GCC - Stroke Related Deaths by Countries, 2017
Figure 2-79: GCC - Stroke Related Deaths by Countries (%), 2017
Figure 2-80: GCC - Obese Population by Countries (%), 2019
Figure 2-81: GCC - Body Mass Index by Countries, 2019
Figure 2-82: Saudi Arabia - Obesity Prevalence Rate (%), 2017 and 2022
Figure 2-83: Saudi Arabia - Obesity Prevalence Rate by Gender (%), 2017 and 2022
Figure 2-84: UAE - Prevalence Rate of Obesity and Overweight by Gender(%), 2016
Figure 2-85: UAE - Obese Adult Population (%), 2019
Figure 2-86: Kuwait - Prevalence Rate of Obesity and Overweight (%), 2016
Figure 2-87: Kuwait - Prevalence Rate of Obesity and Overweight by Gender (%), 2016
Figure 2-88: Bahrain - Prevalence Rate of Obesity and Overweight (%), 2016
Figure 2-89: Bahrain - Prevalence Rate of Obesity and Overweight by Gender (%), 2016
Figure 2-90: Qatar - Prevalence Rate of Obesity and Overweight (%), 2016
Figure 2-91: Qatar - Prevalence Rate of Obesity and Overweight by Gender (%), 2016
Figure 2-92: Oman - Obesity Prevalence Rate by Gender (%), 2016
Figure 2-93: GCC - Asthma Related Deaths by Countries, 2017
Figure 2-94: GCC - Asthma Related Deaths by Countries (%), 2017
Figure 2-95: GCC - Age Standardized Asthma Death Rate by Countries (per 100,000 People), 2017
Figure 2-96: GCC - Tuberculosis Related Deaths by Countries, 2017
Figure 2-97: GCC - Age Standardized Incidence Rate of Tuberculosis by Countries (Per 100,000 People), 2017
Figure 2-98: GCC - Asthma Related Deaths by Countries (%), 2017
Figure 2-99: GCC - Age Standardized Tuberculosis Death Rate by Countries (per 100,000 People), 2017
Figure 2-100: GCC - Influenza and Pneumonia Related Deaths by Countries, 2017
Figure 2-101: GCC - Influenza and Pneumonia Related Deaths by Countries (%), 2017
Figure 2-102: GCC - Age Standardized Influenza and Pneumonia Death Rate by Countries (per 100,000 People), 2017
Figure 2-103: GCC - COPD Prevalence Rate by Countries (%), 2018
Figure 2-104: GCC - COPD and Cystic Fibrosis Related Deaths by Countries, 2017
Figure 2-105: GCC - COPD and Cystic Fibrosis Related Deaths by Countries (%), 2017
Figure 2-106: GCC - Age Standardized COPD and Cystic Fibrosis Death Rate by Countries (per 100,000 People), 2017
Figure 2-107: GCC - Alzheimer/Dementia Related Deaths by Countries, 2017
Figure 2-108: GCC - Alzheimer/Dementia Related Deaths by Countries (%), 2017
Figure 2-109: GCC - Age Standardized Alzheimer/Dementia Death Rate by Countries (per 100,000 People), 2017
Figure 3-1: GCC - Types of Drug Registration Process
Figure 3-2: Process Map for GCC Centralized Registration
Figure 3-3: GCC - Innovative/Biological and Generic Drug Registration Fees for Evaluation Procedures (SAR/US$), 2019
Figure 3-4: GCC - Innovative/Biological and Generic Drug Registration Renewal Fees (SAR/US$), 2019
Figure 3-5: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength and New Pack Size for Innovative/Biological Products (SAR/US$), 2019
Figure 3-6: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength and New Pack Size for Generic Products (SAR/US$), 2019
Figure 3-7: GCC - Registration Fees for Addition of New Pharmaceutical Form, New Strength and New Pack Size for Intravenous Generic Products (SAR/US$), 2019
Figure 3-8: Saudi Arabia - Regulatory Process for Pharmaceuticals
Figure 3-9: Kuwait - Regulatory Process for Pharmaceuticals
Figure 3-10: UAE - Regulatory Process for Pharmaceuticals
Figure 3-11: Bahrain - Regulatory Process for Pharmaceuticals
Figure 3-12: Qatar - Regulatory Process for Pharmaceuticals
Figure 3-13: Oman - Regulatory Process for Pharmaceuticals
